Phathom Pharmaceuticals

Phathom Pharmaceuticals

Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

$378.8M

Market Cap • 11/20/2026

2018

(8 years)

Founded

2019

(7 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

1,4

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

378,8M

EV

362,2M

EV/Revenue

1,3

EV/EBITDA

-14,5

EV/EBIT

-14,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-33,3%

Total Yield

-33,3%

Payout

0%

Retained Earnings

-1,5B

Profitability

Gross Margin

80,7%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

11,6%

Capex/Revenue

0,1%

Capex/D&A

64%

Capex/OCF

-1,5%

SBC/OCF

—

% PPE

0,9%

% Goodwill

0%

ROE

21,6%

ROIC

—

Growth

CAGR Op. Income 5Y

-30,3%

CAGR Net Income 5Y

-12,5%

CAGR EPS 5Y

-25,6%

CAGR OCF 5Y

-31,3%

Leverage

N.D./EBITDA

0,7

Debt/Equity

0%

Current Ratio

1,8

Quick Ratio

1,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium